Tectonic Therapeutic Q2 FY26 net loss widens to $22.29 million

Reuters2026/08/06 20:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tectonic Therapeutic posted a Q2 net loss of USD 22.29 million, widening from USD 19.98 million a year earlier; loss per share was USD 1.18.
R&D expense rose 5.02% to USD 18.05 million, while G&A climbed 19.87% to USD 6.17 million.
Cash and cash equivalents fell to USD 227.07 million at June 30 from USD 236.9 million at March 31; runway seen into Q1 2029.
Completed enrollment in the TX45 APEX Phase 2 PH-HFpEF trial; topline data expected early Q1 2027, with the IDMC recommending continuation unchanged.
Finished dosing six single-dose cohorts in the TX2100 Phase 1a healthy-volunteer study; topline results expected by end of Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061601PRIMZONEFULLFEED9805460) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tectonic Therapeutic Q2 FY26 net loss widens to $22.29 million

You may also like

Crypto prices